MX381260B - Inhibidores heterociclicos de glutaminasa. - Google Patents
Inhibidores heterociclicos de glutaminasa.Info
- Publication number
- MX381260B MX381260B MX2015005963A MX2015005963A MX381260B MX 381260 B MX381260 B MX 381260B MX 2015005963 A MX2015005963 A MX 2015005963A MX 2015005963 A MX2015005963 A MX 2015005963A MX 381260 B MX381260 B MX 381260B
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic
- glutaminase inhibitors
- glutaminase
- inhibitors
- immunological
- Prior art date
Links
- 102000009127 Glutaminase Human genes 0.000 title abstract 2
- 108010073324 Glutaminase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se describen compuestos heterocíclicos que contienen anillos de tiadiazol y/o piridazina, así como preparaciones farmacéuticas de los mismos. Los compuestos en la presente se hacen además conocidos por ser útiles como inhibidores de glutaminasa con usos potenciales en el tratamiento de cáncer, enfermedades inmunológicas y neurológicas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727195P | 2012-11-16 | 2012-11-16 | |
| US201361824434P | 2013-05-17 | 2013-05-17 | |
| PCT/US2013/070277 WO2014078645A1 (en) | 2012-11-16 | 2013-11-15 | Heterocyclic glutaminase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005963A MX2015005963A (es) | 2015-09-16 |
| MX381260B true MX381260B (es) | 2025-03-12 |
Family
ID=50731715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005963A MX381260B (es) | 2012-11-16 | 2013-11-15 | Inhibidores heterociclicos de glutaminasa. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10793535B2 (es) |
| EP (2) | EP3954686A1 (es) |
| JP (1) | JP6275153B2 (es) |
| KR (1) | KR102220175B1 (es) |
| CN (1) | CN105051041B (es) |
| AU (1) | AU2013344560B2 (es) |
| BR (1) | BR112015010955A2 (es) |
| CA (1) | CA2891667A1 (es) |
| CY (1) | CY1125279T1 (es) |
| DK (1) | DK2920168T3 (es) |
| EA (1) | EA029707B1 (es) |
| ES (1) | ES2899461T3 (es) |
| HR (1) | HRP20211610T1 (es) |
| HU (1) | HUE056078T2 (es) |
| IL (1) | IL238787A0 (es) |
| LT (1) | LT2920168T (es) |
| MX (1) | MX381260B (es) |
| PL (1) | PL2920168T3 (es) |
| PT (1) | PT2920168T (es) |
| RS (1) | RS62447B1 (es) |
| SG (1) | SG11201503720SA (es) |
| SI (1) | SI2920168T1 (es) |
| SM (1) | SMT202100589T1 (es) |
| WO (1) | WO2014078645A1 (es) |
| ZA (2) | ZA201504294B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| PT2920168T (pt) | 2012-11-16 | 2021-10-18 | Calithera Biosciences Inc | Inibidores heterocíclicos de glutaminase |
| SG11201504184PA (en) * | 2012-12-03 | 2015-06-29 | Calithera Biosciences Inc | Treatment of cancer with heterocyclic inhibitors of glutaminase |
| CA2934702A1 (en) | 2014-01-06 | 2015-07-09 | Rhizen Pharmaceuticals Sa | Inhibitors of glutaminase |
| WO2015166373A1 (en) * | 2014-04-30 | 2015-11-05 | Pfizer Inc. | Cycloalkyl-linked diheterocycle derivatives |
| GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| EA036001B1 (ru) * | 2014-06-13 | 2020-09-11 | Калитера Байосайенсиз, Инк. | Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких |
| US20160002248A1 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, The University Of Texas System | Gls1 inhibitors for treating disease |
| EP3164195B1 (en) * | 2014-07-03 | 2022-06-15 | Board of Regents, The University of Texas System | Glutaminase inhibitor therapy |
| CN107074805B (zh) | 2014-07-03 | 2021-02-26 | 德州大学系统董事会 | 用于治疗疾病的gls1抑制剂 |
| WO2016007647A1 (en) * | 2014-07-09 | 2016-01-14 | The Johns Hopkins University | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy |
| CA2957225A1 (en) | 2014-08-07 | 2016-02-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| EP3277276B1 (en) * | 2015-03-30 | 2020-11-04 | Calithera Biosciences, Inc. | Methods of administering glutaminase inhibitors |
| SG11201708153XA (en) | 2015-04-06 | 2017-11-29 | Calithera Biosciences Inc | Treatment of lung cancer with inhibitors of glutaminase |
| EP3316887B1 (en) * | 2015-06-30 | 2020-04-08 | Board of Regents, The University of Texas System | Gls1 inhibitors for treating disease |
| JP6971239B2 (ja) | 2015-10-05 | 2021-11-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法 |
| US10323028B2 (en) * | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| TW201730188A (zh) * | 2015-11-30 | 2017-09-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| BR112018012660B1 (pt) | 2015-12-22 | 2023-12-19 | Board Of Regents, The University Of Texas System | Sal, solvato, ou polimorfo de um composto; polimorfo de composto sólido; composição; e uso de um sal, solvato ou polimorfo |
| US10278968B2 (en) * | 2016-08-25 | 2019-05-07 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| CN109982703A (zh) | 2016-08-25 | 2019-07-05 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂的组合疗法 |
| WO2018039442A1 (en) * | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Treatment of cancer with inhibitors of glutaminase |
| WO2018228435A1 (zh) * | 2017-06-13 | 2018-12-20 | 南京明德新药研发股份有限公司 | 作为gls1抑制剂的化合物 |
| US10722487B2 (en) | 2017-10-18 | 2020-07-28 | Board Of Regents, The University Of Texas System | Glutaminase inhibitor therapy |
| CN110746416A (zh) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
| CN114805346A (zh) * | 2021-07-08 | 2022-07-29 | 成都硕德药业有限公司 | 杂环类衍生物、其制备方法及用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1019519A (en) | 1911-07-11 | 1912-03-05 | Oscar Martin Polin | Apparatus for making backing for teeth. |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| ATE391492T1 (de) | 1997-07-29 | 2008-04-15 | Alcon Lab Inc | Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat |
| US6310093B1 (en) | 1997-08-29 | 2001-10-30 | Elan Pharmaceuticals, Inc. | Method of preventing neuronal death |
| EP1051167A1 (en) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-) -bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| ES2593113T3 (es) | 2003-08-07 | 2016-12-05 | Allergan, Inc. | Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| JP4885122B2 (ja) | 2004-04-15 | 2012-02-29 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 癌、器官傷害、および筋肉リハビリテーション／運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー |
| US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US20110281234A1 (en) | 2010-05-12 | 2011-11-17 | Colton Crane | System and methods for removing a loose tooth |
| US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| FI20115876A0 (fi) | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Yhdistelmähoito |
| HUE047642T2 (hu) * | 2011-11-21 | 2020-05-28 | Calithera Biosciences Inc | A glutamináz heterociklusos gátlói |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| PT2920168T (pt) | 2012-11-16 | 2021-10-18 | Calithera Biosciences Inc | Inibidores heterocíclicos de glutaminase |
| CA2892089A1 (en) | 2012-11-21 | 2014-05-30 | Rene M. Lemieux | Glutaminase inhibitors and methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| SG11201504184PA (en) | 2012-12-03 | 2015-06-29 | Calithera Biosciences Inc | Treatment of cancer with heterocyclic inhibitors of glutaminase |
| WO2015061432A1 (en) | 2013-10-25 | 2015-04-30 | Calithera Biosciences, Inc. | Treatment of viral infections with inhibitors of glutaminase |
| WO2015138902A1 (en) | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| EA036001B1 (ru) | 2014-06-13 | 2020-09-11 | Калитера Байосайенсиз, Инк. | Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких |
| CA2957225A1 (en) | 2014-08-07 | 2016-02-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| EP3277276B1 (en) | 2015-03-30 | 2020-11-04 | Calithera Biosciences, Inc. | Methods of administering glutaminase inhibitors |
| SG11201708153XA (en) | 2015-04-06 | 2017-11-29 | Calithera Biosciences Inc | Treatment of lung cancer with inhibitors of glutaminase |
| JP6971239B2 (ja) | 2015-10-05 | 2021-11-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法 |
| US10278968B2 (en) | 2016-08-25 | 2019-05-07 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| KR20190125432A (ko) | 2017-03-10 | 2019-11-06 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 글루타미나제 억제제를 사용하는 병용 요법 |
-
2013
- 2013-11-15 PT PT138550397T patent/PT2920168T/pt unknown
- 2013-11-15 SG SG11201503720SA patent/SG11201503720SA/en unknown
- 2013-11-15 KR KR1020157015874A patent/KR102220175B1/ko active Active
- 2013-11-15 EA EA201590941A patent/EA029707B1/ru not_active IP Right Cessation
- 2013-11-15 JP JP2015542813A patent/JP6275153B2/ja active Active
- 2013-11-15 SI SI201331934T patent/SI2920168T1/sl unknown
- 2013-11-15 CA CA2891667A patent/CA2891667A1/en not_active Abandoned
- 2013-11-15 RS RS20211273A patent/RS62447B1/sr unknown
- 2013-11-15 ES ES13855039T patent/ES2899461T3/es active Active
- 2013-11-15 HR HRP20211610TT patent/HRP20211610T1/hr unknown
- 2013-11-15 AU AU2013344560A patent/AU2013344560B2/en active Active
- 2013-11-15 WO PCT/US2013/070277 patent/WO2014078645A1/en not_active Ceased
- 2013-11-15 EP EP21184626.6A patent/EP3954686A1/en not_active Withdrawn
- 2013-11-15 US US14/081,175 patent/US10793535B2/en active Active
- 2013-11-15 DK DK13855039.7T patent/DK2920168T3/da active
- 2013-11-15 LT LTEPPCT/US2013/070277T patent/LT2920168T/lt unknown
- 2013-11-15 MX MX2015005963A patent/MX381260B/es unknown
- 2013-11-15 HU HUE13855039A patent/HUE056078T2/hu unknown
- 2013-11-15 CN CN201380069950.3A patent/CN105051041B/zh active Active
- 2013-11-15 EP EP13855039.7A patent/EP2920168B1/en active Active
- 2013-11-15 BR BR112015010955A patent/BR112015010955A2/pt not_active Application Discontinuation
- 2013-11-15 PL PL13855039T patent/PL2920168T3/pl unknown
- 2013-11-15 SM SM20210589T patent/SMT202100589T1/it unknown
-
2015
- 2015-05-13 IL IL238787A patent/IL238787A0/en unknown
- 2015-06-12 ZA ZA2015/04294A patent/ZA201504294B/en unknown
-
2016
- 2016-09-23 ZA ZA2016/06590A patent/ZA201606590B/en unknown
-
2020
- 2020-10-05 US US17/063,066 patent/US20210292289A1/en not_active Abandoned
-
2021
- 2021-10-19 CY CY20211100905T patent/CY1125279T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381260B (es) | Inhibidores heterociclicos de glutaminasa. | |
| JOP20200097A1 (ar) | معدل مستقبل أندروجين واستخداماته | |
| MX380469B (es) | Compuestos heterociclos bicíclicos y sus usos en terapia. | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
| GT201500248A (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| MX2016004340A (es) | Compuestos heterociclicos y usos de los mismos. | |
| CO6670585A2 (es) | Promotores de apotosis n-acilsufonamidas | |
| NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| BR112014019990A8 (pt) | Compostos enediinos, seus conjugados e usos e métodos para esses compostos | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| EA201590005A1 (ru) | Замещенные трициклические соединения как ингибиторы fgfr | |
| BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
| MX376008B (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX391858B (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| EA201591616A1 (ru) | Трифторметил-замещенные аннелированные пиримидины и их применение | |
| BR112015027951A8 (pt) | arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit | |
| NZ705040A (en) | Fused pyrimidines as inhibitors of p97 complex | |
| DOP2014000255A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| MX379456B (es) | Inhibidores de fde9 con estructura básica de imidazotriazinona y estructura básica de imidazopirazinona en el tratamiento de enfermedades periféricas. | |
| BR112016001645A8 (pt) | derivados de oxoquinazolinil-butanamida, seu uso, medicamentos e kit | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ |